Related resources and publications
VISTA - safety and PK profiling
Humanized ICP mouse and cell lines
J Allergy Clin Immunol
J Immunother Cancer
The hPD-1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.
The double-humanized PD‑1 and LAG3 (hPD-1/hLAG3) mouse model was generated by intercrossing hPD-1 and hLAG3 mice.
The PD-1 humanized model, developed by Knockin at the mouse Pd‑1 locus, expresses a chimeric PD‑1: human extracellular and mouse transmembrane and intracellular domains.
The LAG3 humanized model, developed by Knockin at the mouse Lag3 locus, expresses the full-length chimeric LAG3 isoform (human extracellular domains, and mouse transmembrane and intracellular domains).
Both hPD-1 and hLAG3 expressions are regulated by endogenous mouse promoters.
Splenocytes from hPD-1/hLAG3 double homozygous mice and wild-type mice were activated with αCD3/αCD28 and cultured in presence of recombinant mIL-2. mPD-1 and hPD-1 expression was evaluated at day 3 on conventional CD4 T cells (viable, CD3+CD4+Foxp3-), Treg cells (viable, CD3+CD4+CD25+Foxp3+) and CD8 T cells (viable, CD3+CD8+).
Splenocytes from hPD-1/LAG3 double homozygous mice and wild-type mice were activated with αCD3/αCD28 and cultured in presence of recombinant mIL-2. mLAG3 and hLAG3 expression was evaluated at day 3 on conventional CD4 T cells (viable, CD3+CD4+Foxp3-), Treg cells (viable, CD3+CD4+CD25+Foxp3+) and CD8 T cells (viable, CD3+CD8+).
VISTA - safety and PK profiling
Humanized ICP mouse and cell lines
J Allergy Clin Immunol
J Immunother Cancer
The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.
Let us know how we can help